Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Journal of Drugs in Dermatology

• Publication date

  2014-12-01

• Fields of study

  Medicine

• Identifiers
  PMID 25607786
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Can suppression of inflammation by anti-TNF prevent progression of subclinical atherosclerosis in inflammatory arthritis?

  2014cited by this paper
• German psoriasis registry PsoBest: objectives, methodology and baseline data

  2014cited by this paper
• Infection risk in Rheumatoid Arthritis and Spondyloarthropathy patients under treatment with DMARDs, Corticosteroids and TNF-α antagonists

  2014cited by this paper
• From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies.

  2014cited by this paper
• OBSERVE-5 interim analysis: an observational postmarketing safety registry of etanercept for the treatment of psoriasis.

  2013cited by this paper
• Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients

  2013cited by this paper
• Long‐term safety of ustekinumab in patients with moderate‐to‐severe psoriasis: final results from 5 years of follow‐up

  2013cited by this paper
• Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate‐to‐severe plaque psoriasis: results of a randomized, long‐term extension trial (RESTORE2)

  2013cited by this paper
• The Burden of Moderate to Severe Psoriasis

  2012cited by this paper
• Integrated safety analysis: short- and long-term safety profiles of etanercept in patients with psoriasis.

  2012cited by this paper
• Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis.

  2012cited by this paper
• PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents.

  2012cited by this paper
• The Long-Term Safety of Adalimumab Treatment in Moderate to Severe Psoriasis

  2011cited by this paper
• Increased risk of infectious disease requiring hospitalization among patients with psoriasis: a population-based cohort.

  2011cited by this paper
• The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials.

  2011cited by this paper
• Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registry

  2011cited by this paper
• From randomized controlled trials to observational studies.

  2009cited by this paper
• The AWARE Study: Methodology and Baseline Characteristics

  2009cited by this paper
• Review and expert opinion on prevention and treatment of infliximab‐related infusion reactions

  2008cited by this paper
• National Registries of Systemic Treatment for Psoriasis and the European ‘Psonet’ Initiative

  2008cited by this paper
• Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis

  2008cited by this paper
• PsoReg – The Swedish Registry for Systemic Psoriasis Treatment

  2007cited by this paper
• Psoriasis Therapy in Real Life: The Need for Registries

  2006cited by this paper
• An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy.

  2005cited by this paper

• Prescribing Practices Among Psoriasis Experts for Patients with Concomitant Malignancy: A Survey of International Psoriasis Council Members.

  2025cites this paper
• Brodalumab: Seven-Year US Pharmacovigilance Report

  2025influential citation
• An assessment of the prescribing preferences of Irish dermatology consultants for the treatment of severe psoriasis in the setting of a cancer diagnosis

  2025cites this paper
• Biologics in the management of pediatric inflammatory bowel disease: When and what to choose

  2025cites this paper
• Serious adverse events associated with systemic treatments for psoriasis: a network meta-analysis of observational studies and randomized controlled trials

  2024cites this paper
• Biologics Versus JAK Inhibitors. Part I: Cancer Risk. A Narrative Review

  2024cites this paper
• Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase 3 poetyk trials.

  2024cites this paper
• Reducing cardiovascular risk in immune‐mediated inflammatory diseases: Tumour necrosis factor inhibitors compared to conventional therapies—A systematic review and meta‐analysis

  2024cites this paper
• Brodalumab: 5-Year US Pharmacovigilance Report

  2024influential citation
• Brodalumab: Six-Year US Pharmacovigilance Report

  2024cites this paper
• GRAPPA Debate: Targeted Small Molecules Versus Biologics as First-Line Systemic Therapy After Conventional Therapy for Moderate-to-Severe Psoriasis.

  2024cites this paper
• Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib

  2023cites this paper
• Sex differences in adverse events from systemic treatments for psoriasis: A decade of insights from the Swiss Psoriasis Registry (SDNTT)

  2023cites this paper
• Five-year safety of tildrakizumab in patients with moderate-to-severe psoriasis from two phase 3 trials (reSURFACE 1 and reSURFACE 2): number needed to harm for occurrence of adverse events of special interest

  2023influential citation
• Efficacy of Tildrakizumab Across Different Body Weights in Moderate-to-Severe Psoriasis Over 5 Years: Pooled Analyses from the reSURFACE Pivotal Studies

  2022cites this paper
• FOR P SORIATIC A RTHRITIS AND P SORIASIS

  2021cites this paper
• The safety profile of biologic agents in comparison with non‐biologic systemic agents, and topical compounds in the management of psoriasis—A 30‐month prospective, observational cohort study

  2021cites this paper
• Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations

  2021cites this paper
• Treatment of inflammatory bowel diseases: focusing on biologic agents and new therapies

  2021cites this paper
• Positioning Biologic Therapies in the Management of Pediatric Inflammatory Bowel Disease.

  2020cites this paper
• Treatment modalities and risk of adverse events associated with biologic therapy: A 10‐year observational review of the Australasian Psoriasis Registry

  2020cites this paper
• Etablierung des Schwerpunktes Psoriasis an der Universitätshautklinik Rostock und eine praxisbezogene Übersicht über die Biologikatherapie der Psoriasis

  2020cites this paper
• Evaluation of ustekinumab treatment in psoriasis and the potential effect of metabolic syndrome on treatment response: a single center retrospective study

  2020cites this paper
• Apremilast for psoriasis treatment.

  2020cites this paper
• Beyond skin deep: addressing comorbidities in psoriasis

  2020cites this paper
• Long term safety of nine systemic medications for psoriasis: a cohort study using the Biobadaderm Registry.

  2020cites this paper
• Anti‐psoriatic therapies and cardiovascular risk: is there a difference between different systemic agents?

  2020cites this paper
• Malignancy Rates in Brodalumab Clinical Studies for Psoriasis

  2020cites this paper
• Etablierung des Schwerpunktes Psoriasis an der Universitäts- hautklinik Rostock und eine praxisbezogene Übersicht über die Biologikatherapie der Psoriasis Establishment of the Psoriasis Center at the Rostock University Dermatological Clinic and a Practical Overview of the Biological Treatment of

  2020cites this paper
• The TNF/IL‐23/IL‐17 axis—Head‐to‐head trials comparing different biologics in psoriasis treatment

  2020cites this paper
• Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities.

  2019cites this paper
• Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia

  2019cites this paper
• Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn’s disease in Asia

  2019cites this paper
• A safety review of recent advancements in the treatment of psoriasis: analysis of clinical trial safety data

  2019cites this paper
• Cost of Refractory Crohn’s Disease Before and After Ustekinumab Utilization

  2019cites this paper
• Serious infections in patients with self-reported psoriatic arthritis from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) treated with biologics

  2019cites this paper
• Kasr AL-Ainy’s psoriasis unit protocol for the treatment of psoriasis, part II: biological therapies

  2019cites this paper
• Latin American Clinical Practice Guidelines on the Systemic Treatment of Psoriasis SOLAPSO – Sociedad Latinoamericana de Psoriasis (Latin American Psoriasis Society)

  2019cites this paper
• Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study

  2019cites this paper
• ЭФФЕКТИВНОСТЬ И БЕЗОПАСНОСТЬ УСТЕКИНУМАБА ПРИ БОЛЕЗНИ КРОНА (обзор литературы)

  2019cites this paper
• Biologic therapy in psoriasis: navigating the options.

  2018cites this paper
• Effect of 2 Psoriasis Treatments on Vascular Inflammation and Novel Inflammatory Cardiovascular Biomarkers: A Randomized Placebo-Controlled Trial

  2018cites this paper
• Psoriasis in Taiwan: From epidemiology to new treatments

  2018cites this paper
• Adverse Reactions to Biologics in Psoriasis.

  2018cites this paper
• Clinical Trial and Registry Data.

  2018cites this paper
• Latest Therapeutics in Plaque Psoriasis: A Review

  2018cites this paper
• Commentary: The Corrona-National Psoriasis Foundation Psoriasis Registry: A new collaborative approach for postapproval registries.

  2018cites this paper
• Biologikanebenwirkungen bei Psoriasis

  2018cites this paper
• Risk of cancer in patients with psoriasis on biological therapies: a systematic review

  2018cites this paper
• Biologics in pediatric psoriasis – efficacy and safety

  2018cites this paper
• Novel Therapies and Treatment Strategies for Patients with Inflammatory Bowel Disease

  2018cites this paper
• Minimal clinically important difference (MCID) for work productivity and activity impairment (WPAI) questionnaire in psoriasis patients

  2018cites this paper
• [Side effects of biologic therapies in psoriasis].

  2018cites this paper
• New therapies versus first-generation biologic drugs in psoriasis: a review of adverse events and their management

  2018cites this paper
• TNF inhibitors for psoriasis

  2018cites this paper
• Utilization of Biologic and Systemic Agents in the Elderly

  2018cites this paper
• Treatment Approaches to Moderate to Severe Psoriasis

  2017cites this paper
• Italian guidelines on the systemic treatments of moderate‐to‐severe plaque psoriasis

  2017cites this paper
• Mechanism of action of the biologics used in the treatment of plaque psoriasis

  2017influential citation
• Psoriasis in the mature patient: Therapeutic approach in the era of biologics.

  2017cites this paper
• Long‐term therapy with ustekinumab for psoriasis in a patient with a history of malignant melanoma

  2017influential citation
• Adverse events associated with discontinuation of the biologics/classic systemic treatments for moderate‐to‐severe plaque psoriasis: data from the Spanish Biologics Registry, Biobadaderm

  2017cites this paper
• Efficacy and safety of ustekinumab in Japanese patients with moderately to severely active Crohn's disease: a subpopulation analysis of phase 3 induction and maintenance studies

  2017cites this paper
• Ustekinumab als Therapeutikum bei Morbus Crohn

  2017cites this paper
• Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta‐analysis of randomized controlled trials

  2017cites this paper
• Long‐term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)

  2017cites this paper
• Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry

  2017cites this paper
• Long-Term Safety and Effectiveness of Adalimumab for Moderate to Severe Psoriasis: Results from 7-Year Interim Analysis of the ESPRIT Registry

  2017cites this paper
• Anti-interleukin and interleukin therapies for psoriasis: current evidence and clinical usefulness

  2017cites this paper
• Ustekinumab to treat Crohn's disease.

  2017cites this paper
• Evaluation of Risk of Major Adverse Cardiovascular Events With Biologic Therapy in Patients With Psoriasis.

  2017cites this paper
• Infliximab biosimilar CT‐P13 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry

  2017cites this paper
• Squamous Cell Carcinoma of the Tongue in a Patient on Ustekinumab as the Treatment of Psoriasis

  2017cites this paper
• Unerwünschte Wirkungen von Biologika bei Psoriasis

  2017cites this paper
• Epigenetic biomarker discovery in inflammatory bowel disease : unearthing clues for disease pathogenesis?

  2017cites this paper
• The NPF/Corrona Psoriasis Registry: A New Collaborative Approach to Post-approval Registries

  2017cites this paper
• Ustekinumab en el tratamiento de la enfermedad de Crohn

  2017cites this paper
• Review of U.S. registries for psoriasis

  2017cites this paper
• Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohn's Disease: Real-world Experience from a Multicenter Cohort Study

  2017cites this paper
• 2015 Publications of the Baylor Scott & White Health North Division Medical and Scientific Staff

  2016cites this paper
• Biologic Therapy for Psoriasis

  2016cites this paper
• Current status and future prospects for biologic treatments of psoriasis

  2016cites this paper
• Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.

  2016cites this paper
• Psoriasis registries worldwide: systematic overview on registry publications

  2016cites this paper
• Therapeutic Targeting of IL-17 and IL-23 Cytokines in Immune-Mediated Diseases.

  2016cites this paper
• Emerging Therapies for Inflammatory Bowel Diseases

  2016cites this paper
• A boxed warning for inadequate psoriasis treatment.

  2016cites this paper
• Demyelinating disorders secondary to TNF-inhibitor therapy for the treatment of psoriasis: A review

  2016cites this paper
• Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis

  2016cites this paper
• Assessment and monitoring of biologic drug adverse events in patients with psoriasis

  2016cites this paper
• Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.

  2016cites this paper
• Necrotizing Fasciitis Erythroderma

  2016cites this paper
• Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).

  2015cites this paper
• Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2015 MauiDerm Meeting.

  2015cites this paper
• Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.

  2015cites this paper
• The Role of the Specialty Pharmacist in Optimizing the Quality of Care for Patients with Psoriasis and Psoriatic Arthritis

  2015cites this paper
• The cost-effectiveness of ustekinumab for moderate-to-severe psoriasis

  2015cites this paper
• Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).

  2015cites this paper
• Apremilast in the treatment of moderate-to-severe plaque psoriasis: results from the ESTEEM studies

  2015cites this paper
• Patient-Centered Approach to Biologics in the Treatment of Psoriasis

  2015influential citation